Glucotrack, Inc.GCTK
Price (close)
$2.58
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$15.9M
Dividend yield
—
1-year total return
-97.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Glucotrack, Inc. does.
Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development
of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and Type 2 diabetes using insulin
Company was founded with a mission to develop Glucotrack®, a non-invasive glucose monitoring device designed to help people with
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$2.7M | -$4.1M | -$4.4M | -$7.1M | -$22.6M | -$19.4M |
| Free cash flow | -$3.6M | -$3.8M | -$3.7M | — | -$12.6M | -$15.3M |
More on GCTK.
- Glucotrack, Inc. summary
- Glucotrack, Inc. financial statements
- Glucotrack, Inc. key metrics
- Glucotrack, Inc. health scores and style box
- Glucotrack, Inc. earnings
- Glucotrack, Inc. dividends
- Glucotrack, Inc. valuation
- Glucotrack, Inc. ownership and insiders
- Glucotrack, Inc. peers
Figures from Glucotrack, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.